How often should ALK patients receive scans to determine if their disease has progressed in various parts of the body?

[powerpress]

(IE/Firefox Users: If you have playback problems, please view on YouTube or try the "Download" button above. Get the latest QuickTime Player.)

The doctors discuss how patients can navigate the tricky waters of stopping therapy while avoiding painful and sometimes life-threatening flare.

[powerpress]

(IE/Firefox Users: If you have playback problems, please view on YouTube or try the "Download" button above. Get the latest QuickTime Player.)

ALK positive lung cancer typically shows up in people who do not appear to be at high risk for the disease, so is this something that a lung cancer patient can pass on to his or her children? The doctors discuss what research shows on this issue.

[powerpress]

Who should be tested for ALK? How is ALK tested and how reliable are the results? In this video, the doctors discuss several issues surrounding the issue of testing for ALK, including what the medical guidelines suggest for testing lung cancer patients for genetic mutations.

Xalkori (crizotinib) was one of the fastest approved drugs in cancer treatment history because of its high efficacy levels in ALK positive lung cancer patients. In this video, the doctors discuss what took place as it raced to approval, as well as the limitations and side effects of the drug.

[powerpress]

Dr. Rosalyn Juergens, McMaster University, discusses the evidence and her personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.

[powerpress]

Dr. Ravi Salgia from the University of Chicago discusses the trend of patients consulting Dr.Google - finding information of varied quality on the internet.

[powerpress]

Dr. Heather Wakelee, from Stanford University, discusses the evidence and her personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.

[powerpress]

Dr. Greg Riely, from Memorial Sloan-Kettering, discusses the evidence and his personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.

[powerpress]

Dr. Karen Kelly of the University of California, Davis, discusses the evidence and her personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.

[powerpress]